by Five Rivers Rx | May 23, 2019 | VAWD
The ongoing legal case has shed new light on the motivations behind, and the execution of, OptumRx’s 2016 requirement. Due Diligence Our observations from the court hearing shows lack of due diligence: OptumRx did not perform extensive research on the impact of...
by Five Rivers Rx | May 9, 2019 | Industry News
We have received a lot of questions over the past few weeks on how the lawsuit is progressing and what it will mean for the industry. Although we do not have any definitive answers yet (a court decision could come as early as June), we do have some highlights from our...
by Five Rivers Rx | Feb 26, 2019 | Uncategorized
A new development in the NABP / OptumRx lawsuit over OptumRx’s VAWD Accreditation requirement has lead to the extension of the de facto “injunction” from OptumRx’s VAWD requirement for the wholesale plaintiffs of that suit. Case Development A review of the...
by Five Rivers Rx | Feb 12, 2019 | Industry News, VAWD
By now, OptumRx’s VAWD Accreditation requirement has become a ubiquitous part of the requirements for doing business in the pharmaceutical supply chain. In reading the policy, however, the requirements are not clear for manufacturers and those companies subject to...
by Five Rivers Rx | Jan 3, 2019 | Industry News, NABP
Three generic drug wholesalers, Oak Drugs (“Oak”), Matrix Distributors (“Matrix”), and Primed Pharmaceuticals (“Primed”) are challenging Optum Rx’s VAWD Requirement. The plaintiffs have recently received encouraging news from the U.S District Court for the District of...
